Sentences with phrase «advanced ovarian cancer patients»

Not exact matches

When patients with advanced ovarian cancer become resistant to one drug, clinicians usually prescribe a new drug.

Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cCancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancercancer.

Paclitaxel and another chemotherapy drug, carboplatin, are considered standard, first - line treatments for advanced ovarian cancer, experts say, and most patients respond to the drugs initially.

«Personalized tumor vaccine shows promise in pilot trial: Vaccine against patients» own tumors triggers a broad response, and induced five - year remission in one patient with advanced ovarian cancer.»

Technology developed at Western University and Lawson Health Research Institute can provide a new window into whether or not patients are responding to treatment for advanced ovarian cancer.

The study was done on 10 patients in advanced stages of ovarian cancer.

«One in five women with ovarian cancer does not undergo surgery, study reveals: Results show survival benefit of surgery for patients regardless of age or advanced disease, and point to barriers to cancer care delivery.»

• Diagnostic laparoscopy for all surgically fit patients with suspected advanced - stage ovarian cancer.

Though smaller in number, some patients with advanced disease and carrying a BRCA mutation may benefit from the same targeted therapy being used today in the clinic to successfully treat some ovarian cancer patients.»

The drugs are already approved for treatment of patients with advanced breast cancer as well as ovarian, pancreatic and certain lung cancers.

The poor survival in advanced ovarian cancer is due both to late diagnosis, as well as to the lack of effective second - line therapy for patients who relapse.

Despite advances in surgery and chemotherapy over the past 20 years, only modest progress has been made in improving overall survival in patients with ovarian cancer.

Most patients diagnosed with advanced ovarian cancer develop platinum resistant / refractory disease.

The LION trial randomized 650 patients with advanced epithelial ovarian cancer and macroscopic complete resection to either systematic pelvic and para-aortic LNE (323 patients in intention - to - treat cohort), or no LNE (324 patients in intention - to - treat cohort).

Systematic lymphadenectomy in patients with advanced ovarian cancer and complete resection does not improve progression - free or overall survival, and should be omitted, according to results of a new study.

«Upfront surgery aiming at macroscopic complete resection is the goal in patients with primary advanced ovarian cancer,» said Philipp Harter, MD, PhD, of the Kliniken Essen - Mitte in Germany, during his presentation of the LION study (abstract 5500) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Systematic lymphadenectomy (LNE) in patients with advanced ovarian cancer and complete resection does not improve progression - free or overall survival (OS), and should be omitted, according to results of a new study.

JCO retracted paper «An Integrated Genomic - Based Approach to Individualized Treatment of Patients With Advanced - Stage Ovarian Cancer» — statistician: Mike West

New Standard of Care A 50 - year - old method for delivering chemotherapy directly into the abdomen was reevaluated for patients with ovarian cancer after a seven - year study of more than 400 patients revealed increased survival rates in patients with advanced ovarian cancer.

We have made progress in the safe use of advanced surgical procedures and can now combine surgery with heated intraperitoneal chemotherapy for selected patients with ovarian cancer.

May 20, 2015 Study adds diabetes drug with anti-cancer effect to ovarian cancer treatment Several recent studies have suggested that metformin, an established drug developed to treat patients with type II diabetes, may provide significant benefits, including increased survival, to patients being treated for advanced cancers.